---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-006294"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2022-03-08T23:59:59+00:00"
generated_at: "2026-06-27T00:38:11.892390+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma names Michael Breen Interim CEO; Gregory Berk becomes President R&D/CMO

## Summary
- Michael Breen named Interim CEO effective March 2, 2022; base compensation raised to $515,000.
- Gregory Berk ceases role as Interim CEO but remains President of R&D and CMO; base salary increased to $437,750.
- Both appointments effective March 2, 2022; no other officer changes disclosed.

## SEC filing metadata
- accession: 0001493152-22-006294
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2022-03-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315222006294/0001493152-22-006294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315222006294/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-006294
- JSON: https://secwatch.observer/filing/0001493152-22-006294.json
- Plain text: https://secwatch.observer/filing/0001493152-22-006294.txt

## Key facts
- Executive change
  Michael Breen was appointed as Interim Chief Executive Officer at GT Biopharma, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: Effective March 2, 2022, the Registrant appointed Michael Breen as the Registrant’s Interim Chief Executive Officer with an increase in his annual base compensation to $515,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000149315222006294/0001493152-22-006294-index.htm
- Executive change
  Gregory Berk changed role as President of Research & Development and Chief Medical Officer at GT Biopharma, Inc..
  - Action: ceased
  - Role: President of Research & Development and Chief Medical Officer
  source text: Gregory Berk, M.D. ceased serving as the Registrant’s Interim Chief Executive Officer, but will continue to serve as the Registrant’s President of Research & Development and Chief Medical Officer, with a cost-of-living increase in his annual base compensation to $437,750.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000149315222006294/0001493152-22-006294-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.